# Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

> **NCT07359040** · — · ACTIVE_NOT_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Neoadjuvant Therapy
- PD-1 Inhibitors
- Immunotherapy

## Interventions

- **DRUG:** Ivonescimab
- **DRUG:** PD-1 Inhibitors

## Key facts

- **NCT ID:** NCT07359040
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-12-21
- **Final completion:** 2027-10-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07359040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07359040, "Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07359040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*